4502 — Takeda Pharmaceutical Share News
0.000.00%
Last trade - 00:00Brief: Takeda Pharmaceutical Conducted Thorough Assessment, Found There Was No Confirmed Causal Relationship To Use Of Adzynma &Patient Death - Spokesperson
US FDA investigates Takeda's blood disorder drug after pediatric death (updated)
US FDA investigates death tied to Takeda's blood disorder drug
Brief: FDA Investigates Death Linked to Adzynma Treatment for Congenital Thrombotic Thrombocytopenic Purpura
Brief: Beacon Biosignals Raises $86 Million to Accelerate AI-Driven Insights into Brain Health
US FDA awards six more fast-track vouchers to speed drug reviews (updated)
US FDA awards six more fast-track vouchers to speed drug reviews (updated)
Table: Takeda Pharma 6-MTH group results (IFRS)
Brief: HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
China's Innovent signs cancer therapy deal with Japan's Takeda (updated)
China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda
Brief: Nabla Bio Signs Second Takeda Collaboration To Advance Ai-Driven Design Of Protein Therapeutics
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership
Brief: Takeda Pharmaceutical To Discontinue Its Cell Therapy Efforts
Takeda Pharmaceutical to exit cell therapy research (updated)
Takeda Pharmaceutical to exit cell therapy research
Bristol Myers, Takeda to pool data for AI-based drug discovery
Brief: Takeda Pharmaceutical: Update On Construction Of New Plasma-Derived Therapies Manufacturing Facility In Juso, Osaka
Shares of Asian drugmakers drop after Trump threatens tariffs (updated)